Telix Pharmaceuticals Logo
Telix Pharmaceuticals Logo
  • Our Company
    • Our Company
    • Purpose, Mission & Values
    • Board & Management
    • Our Technology
    • Sustainability
  • Our Portfolio
    • Our Portfolio
    • Disease Areas
      • Prostate Cancer
      • Kidney Cancer
      • Brain Cancer
      • Musculo-skeletal cancers
    • Clinical Trials
    • Illuccix® & Gozellix®
    • Pipeline
    • Research & Innovation
  • Investor Centre
  • News & Views
  • Careers
    • Careers
    • Find a job
Header Image Frame Header Image Frame

Home ASX Page 23

News & Views

Latest News

Category: ASX

See all

Appendix 4D Financial Report for half-year to 30th June 2019

ASX, News,

Telix Pharmaceuticals Limited is pleased to provide appendix 4D half-year report for the six months ended 30th June...

Read more

Appendix 3B – Issue of shares under Share Purchase Plan

ASX, News,

Telix Pharmaceuticals Ltd is pleased to announce Appendix 3B – Issue of shares under Share Purchase Plan...

Read more

Telix Pharmaceuticals Announces Results of Successful SPP

ASX, News,

Telix Pharmaceuticals Limited is pleased to advise that, at closing on Friday 16th August 2019, subscriptions under the Company’s Share Purchase Plan (“SPP”) totaled approximately $9.6...

Read more

Telix Pharmaceuticals Annual Report 2018

ASX, News,

Telix Pharmaceuticals Limited is pleased to provide its Annual Report...

Read more

Telix Pharmaceuticals Ltd Detailed Program Update January 2019

ASX, News,

Telix Pharmaceuticals Limited is pleased to provide a detailed Program Update January...

Read more

Telix Pharmaceuticals Limited Successfully Completes $50 Million Oversubscribed Initial Public Offering

ASX, News,

Telix Pharmaceuticals Limited (“Telix”, the “Company”), an Australian biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR), has successfully raised...

Read more

Telix Pharmaceuticals Launches $50M Underwritten Initial Public Offering

ASX, News,

Telix Pharmaceuticals Limited is pleased to announce the opening of its Initial Public Offering to raise A$50...

Read more

Telix Pharmaceuticals files $50M Underwritten Initial Public Offering

ASX, News,

Telix Pharmaceuticals is pleased to announce it has filed a $50 million Underwritten Initial Public...

Read more

Telix Pharmaceuticals and CellSight Technologies Conclude Collaboration and License Agreement for VisAcT ImmunoPET Technology

ASX, News,

Telix is pleased to announce the conclusion of collaboration and licensing agreement with CellSight Technologies, Inc. (CellSight) for the VisAcT immunoPET imaging technology...

Read more

Telix and Cyclotek Conclude Radiopharmaceutical Manufacturing Agreement for Australia and New Zealand

ASX, News,

Telix is pleased to announce the completion of a Master Services Agreement with Cyclotek (Aust) Pty Ltd...

Read more

Posts pagination

1 … 22 23 24

Subscribe

* indicates required

By subscribing, you are agreeing to the terms of our Global Privacy Policy and provide consent to receive updates from Telix”

Telix Pharmaceuticals Logo
  • Our Company
  • Contact
  • Our Portfolio
  • Careers
  • Investor Centre
  • News & Views

© Telix Pharmaceuticals Limited. 55 Flemington Road, North Melbourne, VIC 3051, Australia.

The Telix Pharmaceuticals and the Illuccix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved.
This website is intended for corporate communication purposes only and is not intended as promotion or advertising to any audience in any country worldwide.

Privacy Policy. Terms of Use. Cookies Policy. Privacy Settings